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Abstract
 
Background.
 
High-dose chemoradiotherapy
combined with autologous bone marrow transplantation
can cure patients with disseminated, aggressive non-
Hodgkin’s lymphoma in whom first-line chemotherapy
has failed. In contrast, cure is rare with second-line che-
motherapy. It has been suggested that patients with slow
responses to the initial phase of first-line chemotherapy
are at high risk for relapse. Therefore, such patients are
potential candidates for early bone marrow transplan-
tation.
 
Methods.
 
To investigate whether patients with slow
responses, defined as only a partial response after three
courses of cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP), would benefit from early trans-
plantation, we conducted a prospective, randomized tri-
al. The early application of high-dose chemoradiothera-
py and autologous bone marrow transplantation was
compared with the continuation of CHOP therapy for an-
other five courses. Patients with complete responses af-
ter three courses of CHOP (fast responses) and patients
who responded partially but still had tumor-positive mar-
row continued with another five courses of CHOP. The
study end points were the response rate, overall surviv-
al, disease-free survival, and event-free survival.
 
Results.
 
Of 286 patients who could be evaluated for the
rapidity of their response after three courses of CHOP, 38
percent had fast responses, 47 percent had slow respons-
es, and 15 percent had no response. Among 106 patients
with slow responses who had lymphoma-negative marrow,
69 patients (65 percent) were randomized. Seventy-four
percent of the CHOP group and 68 percent of the transplan-
tation group had complete remissions (P
 

 
0.54). At four
years the rates of overall, disease-free, and event-free sur-
vival were 85, 72, and 53 percent, respectively, in the
CHOP group and 56, 60, and 41 percent in the transplan-
tation group (P
 

 
0.10). The disease-free survival in both
groups did not differ significantly from that of nonrandom-
ized patients with fast responses (54 percent at four years).
 
Conclusions.
 
The early application of high-dose, mar-
row-ablative chemoradiotherapy with autologous bone
marrow transplantation does not improve the outcome in
patients with aggressive non-Hodgkin’s lymphoma that
responds slowly to first-line CHOP chemotherapy. (N Engl
J Med 1995;332:1045-51.)
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OMBINATION chemotherapy can cure about 45
percent of patients with disseminated intermedi-
ate-grade or high-grade non-Hodgkin’s lymphoma.
 
1
 
Several institutions have reported that aggressive regi-
mens of chemotherapy containing six to eight drugs
gave better results than the CHOP regimen (which
contains cyclophosphamide, doxorubicin, vincristine,
and prednisone),
 
2-7
 
 but in two large, multicenter, ran-
domized, phase 3 trials
 
8,9
 
 the more aggressive regimens
were not found to be superior to CHOP, which is wide-
ly used as first-line chemotherapy for non-Hodgkin’s
lymphoma. However, CHOP fails to cure the disease
when remissions are incomplete or unstable. Retreat-
ment of patients who have relapsed with second-line,
so-called salvage chemotherapy is generally unsuccess-
ful.
 
10
 
 High-dose chemoradiotherapy with autologous
bone marrow transplantation may, however, cure some
of these patients if they have disease that responds to
chemotherapy.
 
10-18
 
Early in the course of treatment, or even at diagno-
sis, it is important to identify patients who are unlikely
to have complete remissions. These high-risk patients
may benefit from high-dose chemoradiotherapy with
bone marrow transplantation while their lymphomas
can still respond to first-line chemotherapy. It has been
suggested that patients in whom complete remission
occurs rapidly with first-line chemotherapy — i.e.,
within three cycles of conventional chemotherapy —
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have a better chance of cure than patients who respond
more slowly.
 
19,20
 
In 1987 we began assessing the efficacy of high-dose
marrow-ablative therapy combined with autologous
bone marrow transplantation in patients with dissemi-
nated, aggressive non-Hodgkin’s lymphoma who have
slow responses to chemotherapy. All patients were
treated with CHOP, and their responses were evaluat-
ed after three courses. Those with partial responses
were considered to have slow responses, and those with
complete responses after three courses of CHOP were
considered to have fast responses. We report here the
results of a multicenter study in which patients with
slow responses and lymphoma-negative bone marrow
were eligible for random assignment to either another
five courses of CHOP (the standard regimen) or mar-
row-ablative chemoradiotherapy with autologous bone
marrow transplantation.
 
M
 
ETHODS
 
Between January 1987 and April 1994, we enrolled 320 patients in
the study. Patients from 15 to 60 years of age were eligible if they had
measurable, biopsy-confirmed intermediate-grade or high-grade non-
Hodgkin’s lymphoma (groups D through H, according to the classi-
fication system of the Working Formulation),
 
21
 
 including unclassi-
fiable intermediate-grade and high-grade lymphoma, and stage II,
III, or IV disease according to the Ann Arbor classification. The B or
T immunotype was determined in either snap-frozen or paraffin-
embedded tissue with mouse monoclonal antibodies against B-cell
antigens CD20 and MB2 and T-cell antigens CD3 and CD45.
Patients were determined to be ineligible if they had previous che-
motherapy or radiotherapy; a history of low-grade malignant lym-
phoma; group I or J high-grade cancer; prior cancer, except non-mel-
anoma skin cancer or cervical carcinoma stage I; a positive serologic
test for the human immunodeficiency virus; involvement of the cen-
tral nervous system by lymphoma; or severe cardiac, pulmonary, neu-
rologic, or metabolic disease. Informed consent was obtained from all
patients. The pathology slides for 88 percent of the patients under-
went central pathology review. The protocol was approved by the in-
stitutional review board of each center.
Staging of the extent of disease, performed before therapy, includ-
ed a history taking and physical examination; complete blood counts,
including a search for abnormal lymphoid cells in the blood by mor-
phologic and immunologic studies using flow cytometry; tests of renal
and liver function; determination of the erythrocyte sedimentation
rate; measurement of serum albumin and serum electrolytes; protein
electrophoresis and immunoelectrophoresis; measurement of serum
lactate dehydrogenase (upper limit, 250 U per liter); chest radiogra-
phy; computed tomography of the abdomen and thorax; consultation
with an ear, nose, and throat specialist; and bone marrow biopsy and
aspiration from the iliac crest, including immunophenotyping by im-
munoperoxidase. As clinically indicated, lumbar puncture or liver bi-
opsy was performed.
Complete restaging of each patient’s condition was performed af-
ter three courses of CHOP chemotherapy and after the completion
of therapy. During follow-up, staging procedures were repeated in
their entirety at least every six months for the first three years and
thereafter as clinically indicated.
Of the 320 patients enrolled, 34 patients were not eligible for the
following reasons: they did not meet the criteria for entry into the
study (6 patients), they had localized disease (5 patients), they had
been treated before registration (2 patients), they had severe concom-
itant disease (4 patients), or the diagnosis was not confirmed (17 pa-
tients). Thus, 286 patients were eligible for analysis.
 
Treatment Protocol
 
CHOP was administered every 21 days as follows: 750 mg of cyclo-
phosphamide per square meter of body-surface area intravenously on
day 1; 50 mg of doxorubicin per square meter intravenously on day 1;
1.4 mg of vincristine per square meter intravenously on day 1 (maxi-
mal dose, 2.0 mg); and 100 mg of prednisone orally on days 1 through
5. Dose reductions were made as previously described if there was
hematologic toxicity
 
22
 
; however, the first course was given in full. If
there was mild neurotoxicity (i.e., paresthesias or decreased tendon
reflexes), the dose of vincristine was reduced to 50 percent, and if
there was severe neurotoxicity (i.e., marked loss of motor function),
the vincristine was omitted. All patients were to receive three courses
of CHOP and were then to be evaluated for their response.
To assess the response to CHOP, all tests that had abnormal re-
sults on staging before therapy were repeated. Complete remission
was defined as the disappearance of all clinical evidence (physical
and radiographic) of disease. Lymph nodes less than 1 cm in diame-
ter on radiography were considered uninvolved. Patients with residu-
al abnormalities detected with computed tomography, especially pa-
tients with bulky disease (tumor 
 

 
10 cm) at diagnosis, were not
considered to be in complete remission unless the abnormality had
decreased in size by 90 percent or more or unless biopsy proved it to
be uninvolved. Partial remission was defined as a reduction by at
least 25 percent of the sum of the largest tumor diameters. Progres-
sive disease was defined as an increase of at least 25 percent in the
size of the original tumor mass or as the development of new lesions.
Patients who did not meet any of the preceding definitions were clas-
sified as having no response.
When they had completed the evaluation after the third cycle of
CHOP, patients with partial remissions and no bone marrow infiltra-
tion were asked about entering the trial. Those who agreed to do so
were randomized. The patients randomly assigned to transplantation
underwent bone marrow collection as soon as complete marrow re-
population had occurred. They were given a fourth course of CHOP
the day after the collection. They then received high-dose chemother-
apy, radiation, and infusion of autologous marrow.
Patients randomly assigned to CHOP began their fourth course on
schedule. Those who had complete remissions and those with partial
responses but with marrow involvement were treated with five addi-
tional courses of CHOP. Patients who had no response or whose dis-
ease progressed were not studied further and were given other ther-
apy at the discretion of the investigators.
Bone marrow collection and cryopreservation were performed as
soon as the marrow was repopulated after the third course of
CHOP.
 
12
 
 At least 2
 

 
10
 
8
 
 nucleated cells per kilogram of body weight
were collected. Reference samples of cells were frozen in small am-
pules and thawed during the first week after freezing in order for the
investigators to check the quality of cryopreservation (with myeloid
and erythroid colony growth in vitro). The absence of marrow in-
volvement by the lymphoma was checked again at the time of the
marrow collection by histologic and cytologic methods. None of the
patients assigned to transplantation had detectable marrow involve-
ment at the time of the marrow collection.
So that there would be time after the collection to evaluate the
quality of the marrow graft and prepare for transplantation, the pa-
tients randomly assigned to transplantation received a fourth course
of CHOP immediately after the bone marrow collection. The condi-
tioning regimen for transplantation was scheduled to be carried out
within six weeks after the fourth course of CHOP.
The high-dose chemoradiotherapy administered before the reinfu-
sion of autologous marrow consisted of cyclophosphamide (60 mg per
kilogram, infused on each of two consecutive days), followed two days
later by total-body irradiation (800 cGy in one fraction). The autol-
ogous (unpurged) marrow graft was thawed rapidly and reinfused
through a central venous catheter the day after the total-body irra-
diation.
 
Statistical Analysis
 
The study was designed on the assumption that for patients in par-
tial remission after three courses of CHOP, two-year event-free surviv-
al would be improved from 35 percent with the continuation of CHOP
to 70 percent with bone marrow transplantation, which would mean an
improvement for patients with slow responses so that their outcome
would be equivalent to that of patients with fast responses.
 
19
 
 Therefore,
a total of 60 patients had to be randomly assigned to the two treat-
ments for the study to have a power of 80 percent to detect such a dif-
ference with a one-sided test at a significance level of 0.05. It was ex-
pected that 25 percent of the patients would have partial remissions
without marrow infiltration after three courses of CHOP. Thus, accord-
ing to estimates before the study began, about 240 patients had to be
enrolled for the induction treatment with CHOP in order to meet the
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objective of 60 randomized patients. Eventual-
ly, 286 eligible patients were enrolled, 106 of
whom (37 percent) had partial remissions
without marrow infiltration and 69 of whom
(24 percent) were randomized.
No further patients were admitted to the
study after December 31, 1993. The data
were analyzed in April 1994, with the last fol-
low-up data available for all patients still
alive, except two patients (not randomized)
who were lost to follow-up after one year. The
median duration of follow-up for the 181 pa-
tients still alive at the final update was three
years (range, two months to seven years). Six-
ty-one patients had follow-up of more than
four years.
Logistic-regression analysis, univariate and
multivariate, was used to test and determine
the strength of the association between the
probability of complete remission and prog-
nostic factors and to determine the difference
between the treatment groups. In these anal-
yses, only complete remissions in patients
treated according to the protocol were con-
sidered — i.e., complete remission after three
courses of CHOP, after continuing treatment
with CHOP, or after bone marrow transplan-
tation for patients in partial remission after
the first three cycles of CHOP. Patients
whose complete remissions occurred only lat-
er, with second-line treatment, were classified
as having no complete remission.
The actuarial method of Kaplan and Meier
was used to calculate probabilities of survival.
Cox regression analysis was used for statisti-
cal tests and the analysis of prognostic fac-
tors. The following end points were analyzed:
overall survival, with failure defined as death
from any cause; disease-free survival, which
was restricted to patients entering complete
remission while being treated according to
the protocol, with failure defined as relapse or
death during a first complete remission; and
event-free survival, with failure defined as no
complete remission during treatment accord-
ing to the protocol, relapse after a complete
remission, or death during a first complete re-
mission. Time was measured from the start
of the first treatment with CHOP or, in the
comparison of the randomized treatment
groups, from the time of randomization. Dis-
ease-free survival was measured from the
date of complete remission. From the esti-
mate of the relative death rate (R) in the
transplantation (ABMT) group as compared
with the CHOP group, obtained from the
Cox model, the corresponding difference in
overall survival (OS) between the two groups
(OS
 
ABMT
 

 
 OS
 
CHOP
 
) was calculated by the for-
mula OS
 
ABMT
 

 
OS
 
R
CHOP 
 
. In this formula, the
overall survival after CHOP therapy was set
at 70 percent. The 95 percent confidence
interval for this difference in survival was calculated by substituting
for R the 95 percent confidence intervals of the estimated relative
death rate.
The following variables were included in the analysis of prognostic
factors: age, sex, histologic grade of cancer (i.e., intermediate vs.
high), Ann Arbor stage, number of extranodal sites, bone marrow
involvement, bulky disease, immunologic phenotype, serum concen-
tration of lactate dehydrogenase, and performance status (assessed
according to the classification system of the World Health Organiza-
tion). For all the statistical tests, a significance level of 0.05 was used.
All reported P values are two-sided and unadjusted.
Interim analyses with rules for stopping in the event of extreme
differences in outcome favoring the transplantation group were
planned and performed twice during the study. The statistical crite-
rion for stopping the accrual of patients was an improvement in over-
all survival in the transplantation group that was statistically signif-
icant at the level of P
 

 
0.005. Because of this stringent criterion, no
adaptation of the nominal significance levels at the final evaluation
was required.
 
R
 
ESULTS
 
Response after Three Courses of CHOP Chemotherapy
 
Table 1 shows the characteristics of all 286 eligible
patients at diagnosis and the subgroups of patients ac-
cording to their responses after three courses of CHOP.
Among the 286 patients, 110 (38 percent) had com-
 
*The median age of the patients was 45 years (range, 15 to 60).
†According to the classification system of the Working Formulation.
 
21
 
‡According to the classification system of the World Health Organization.
§As defined by the International Non-Hodgkin’s Lymphoma Prognostic Factors Project.
 
23
 
Table 1. Characteristics of the 286 Patients According to Their Responses after Three
Courses of CHOP Chemotherapy.
 
*
 
C
 
HARACTERISTIC
 
R
 
ESPONSE
 
 
 
AND
 
 R
 
ANDOMIZATION
 
 S
 
TATUS
COMPLETE 
REMISSION 
 
(
 
N
 

 
110
 
)
 
PARTIAL REMISSION, 
RANDOMIZED
PARTIAL 
REMISSION, 
NONRAN-
DOMIZED
 
(
 
N
 

 
37
 
)
 
PARTIAL 
REMISSION, 
MARROW 
INVOLVE-
MENT
 
(
 
N
 

 
27
 
)
 
PROGRES-
SION 
OR NO 
RESPONSE
 
(
 
N
 

 
43
 
)
 
ALL 
PATIENTS
 
(
 
N
 

 
286
 
)
CHOP
(n
 

 
35)
Trans-
plantation
(n
 

 
34)
 
percentage of patients in group
 
Sex
Male
Female
64
36
63
37
56
44
54
46
70
30
74
26
64
36
Tumor histology†
Follicular, large cell
Diffuse, small cleaved cell
Diffuse, mixed
Diffuse, large cell
Unclassifiable, intermediate 
grade
Immunoblastic
Unclassifiable, high grade
5
4
11
39
4
34
3
17
3
14
26
3
20
17
4
3
23
38
9
20
3
8
5
8
40
10
24
5
26
19
33
11
4
7
0
7
12
21
23
3
26
9
9
6
16
33
5
25
6
Stage
II
III
IV
53
24
23
43
26
31
50
18
32
35
24
41
0
0
100
23
14
63
40
20
40
Extranodal sites (no.)
0
1
2–4
64
23
13
49
37
14
50
35
15
57
16
27
48
23
29
30
42
28
53
28
19
Bone marrow involvement
No
Yes
93
7
94
6
89
11
91
9
0
100
67
33
80
20
Immunologic phenotype
B-cell
T-cell
Neither
Unknown
64
20
3
13
77
3
0
20
79
9
0
12
62
24
0
14
67
11
0
22
67
19
0
14
68
16
1
15
B symptoms
Absent
Present
60
40
68
32
56
44
51
49
63
37
42
58
57
43
Lactate dehydrogenase (U/liter)
 

 
250
250 to 
 

 
750
 

 
750
42
51
7
17
59
24
20
62
18
27
62
11
26
67
7
23
49
28
30
56
14
Bulky disease (tumor 
 

 
10 cm)
No
Yes
76
24
54
46
41
59
59
41
63
37
69
31
65
35
Performance status‡
0
1
2–4
49
43
8
43
51
6
38
53
9
46
41
13
56
41
3
33
39
28
45
44
11
International Index§
Low
Low intermediate
High intermediate
High
25
43
28
4
3
53
41
3
9
47
41
3
10
38
41
11
0
26
70
4
7
30
37
26
13
40
39
8
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plete remissions after the first three courses of CHOP,
133 (47 percent) had partial remissions, and 43 (15
percent) had either no response or progression of dis-
ease (Table 2). Of the 133 patients who had partial re-
sponses, 27 still had lymphoma in the bone marrow
and were therefore ineligible for randomization. Thus,
106 patients qualified for randomization, and 69 of
them (65 percent) were randomized. Thirty-seven
patients (35 percent) were not randomized for the fol-
lowing reasons: refusal by the patient (22 patients),
psychological reasons (4), medical reasons (5), and ad-
ministrative errors (6).
 
Response of the Randomized Patients
 
Table 1 shows the clinical features of the patients
randomly assigned to CHOP or bone marrow trans-
plantation. The two groups were well balanced, espe-
cially with regard to the prognostic variables defined by
the international index established by the International
Non-Hodgkin’s Lymphoma Prognostic Factors Proj-
ect.
 
23
 
 At randomization, 35 patients were assigned to
continue standard treatment with CHOP, and 34 pa-
tients were assigned to transplantation. However, eight
patients assigned to the transplantation group did not
proceed to that treatment; three declined the treat-
ment, and five had progressive disease. Of the patients
assigned to CHOP who continued that treatment, sev-
en patients did not complete all eight courses because
of progressive disease.
The conditioning regimen for transplantation was
started a median of 27 days (range, 17 to 60) after the
fourth course of CHOP. In fact, 26 of 28 patients start-
ed the conditioning regimen within 39 days after the
fourth course of CHOP. The results were analyzed on
an intention-to-treat basis. Twenty-six of the 35 pa-
tients (74 percent) randomly assigned to CHOP had
complete remissions, as compared with 23 of the 34
patients (68 percent) randomly assigned to transplan-
tation (Table 2). This difference was not significant
(P
 

 
0.54). The exclusion of the 15 patients who did not
complete the treatment as planned could have biased
the outcome, because 12 of these patients had early
progressive disease. Analysis according to actual treat-
ments did not change the results; among the 28 pa-
tients in the CHOP group who completed eight courses
of CHOP, 26 reached complete remission, 6 relapsed,
and only 1 died, whereas among the 26 patients in the
transplantation group who underwent transplantation,
23 reached complete remission, 7 relapsed, and 9 died.
 
Survival of the Randomized Patients
 
The mean (
 

 
SE) estimated overall survival four
years from randomization was 85
 

 
6 percent in the
CHOP group and 56
 

 
10 percent in the transplanta-
tion group (Fig. 1). Disease-free survival at four years
was 72
 

 
10 percent in the CHOP group and 60
 

 
12
percent in the transplantation group. Event-free surviv-
al at four years was 53
 

 
9 percent in the CHOP group
and 41
 

 
10 percent in the transplantation group (Fig.
2). There were no significant differences between the
two treatment methods in overall survival (hazard
ratio for transplantation vs. CHOP, 2.2; 95 percent
confidence interval, 0.82 to 5.9; P
 

 
0.12), disease-free
survival (hazard ratio, 1.5; 95 percent confidence inter-
val, 0.49 to 4.3; P
 

 
0.50), or event-
free survival (hazard ratio, 1.3; 95
percent confidence interval, 0.66 to
2.61; P
 

 
0.43). Six patients in the
CHOP group and seven patients in
the transplantation group relapsed.
Six patients assigned to the CHOP
group died, all of lymphoma, where-
as 12 patients in the transplantation
group died, 10 of lymphoma and
2 of treatment-related toxic effects.
 
Response of the Nonrandomized 
Patients
 
The 110 patients in complete re-
mission, the 27 patients with partial
responses and marrow involvement,
and the 37 nonrandomized patients
 
*NA denotes not applicable.
 
Table 2. Treatment Outcome According to the Response after Three Courses of
CHOP Chemotherapy.
 
*
 
V
 
ARIABLE
 
R
 
ESPONSE
 
 
 
AND
 
 R
 
ANDOMIZATION
 
 S
 
TATUS
COMPLETE 
REMISSION 
 
(
 
N
 

 
110
 
)
 
PARTIAL 
REMISSION, RANDOMIZED 
PARTIAL 
REMISSION, 
NONRAN-
DOMIZED
 
(
 
N
 

 
37
 
)
 
PARTIAL 
REMISSION, 
MARROW 
INVOLVEMENT
 
(
 
N
 

 
27
 
)
 
PROGRESSION 
OR NO 
RESPONSE
 
(
 
N
 

 
43
 
)
CHOP
(n
 

 
35)
Trans-
plantation
(n
 

 
34)
 
no. of patients
 
Complete remission after CHOP or 
transplantation
NA 26 23 23 10 NA
Relapse after complete remission 44 6 7 5 4 NA
Death
Treatment-related toxic effects
Lymphoma
Other
35
4
30
1
6
0
6
0
12
2
10
0
14
2
11
1
9
3
4
2
29
1
23
5
 
Figure 1. Overall Survival from the Time of Randomization, Ac-
Pr
op
or
tio
n 
Su
rv
ivi
ng
Months
1.0
0.8
0.6
0.4
0.2
0.0
0 12 24 36 48 60
Transplantation
CHOP
 
cording to Treatment Group.
Among 35 patients assigned to receive eight courses of CHOP
and 34 patients assigned to receive high-dose chemoradiother-
apy and autologous bone marrow transplantation, there were
6 and 12 deaths, respectively.
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with partial responses but no marrow involvement
were all scheduled to continue with another five courses
of CHOP (Table 2). Among the 110 patients in com-
plete remission, 44 patients (40 percent) relapsed dur-
ing CHOP treatment or thereafter. Among the 27 pa-
tients with partial responses but with bone marrow
involvement, 10 patients (37 percent) had complete re-
missions. The rate of complete remission in these pa-
tients was significantly lower (P
 

 
0.006) than that in
the patients who had partial remissions but who had no
marrow infiltration. Among the 37 nonrandomized pa-
tients with partial responses and no bone marrow in-
volvement, 23 (62 percent) had complete remissions
during CHOP therapy. For these 37 patients, overall,
disease-free, and event-free survival at four years was
55, 70, and 43 percent, respectively.
 
Survival of the Eligible Patients
 
Among all 286 study patients, actuarial overall sur-
vival at four years was 59
 

 
3 percent (Fig. 3), and for
the 192 patients with complete responses disease-free
survival at four years was estimated to be 58
 

 
3 per-
cent. For the nonrandomized group of patients with
fast responses (those in complete remission after three
courses of CHOP), disease-free survival at four years
was 54
 

 
5 percent. Table 2 shows the causes of death
in the various treatment groups. Figure 4 shows that
there was no significant difference in survival between
patients in complete remission after three courses of
CHOP (those with fast responses) and patients with
partial (slow) responses. The outcome in patients with
either no response or progressive disease was signifi-
cantly worse (P
 

 
0.001) than in patients who had com-
plete or partial remissions.
 
Analysis of Prognostic Factors
 
Multivariate analysis showed that for all eligible pa-
tients enrolled in the study, the following prognostic
factors were predictive of overall survival: Ann Arbor
stage (II vs. III vs. IV; P
 
0.001), histologic grade of
cancer (intermediate vs. high; P0.01), serum concen-
tration of lactate dehydrogenase (750 vs. 750 U per
liter; P0.001), and performance status (0 or 1 vs. 2, 3,
or 4; P0.001). Other prognostic factors did not have
additional predictive value. Except for the grade of can-
cer, these prognostic factors agree with those defined by
the international index.23 Adjustment for these factors
did not affect the nonsignificant differences between
the randomized treatment groups.
DISCUSSION
We assessed the value of early intervention with
high-dose, marrow-ablative chemoradiotherapy and au-
tologous bone marrow transplantation in patients with
disseminated, aggressive non-Hodgkin’s lymphoma who
had slow responses to standard CHOP chemotherapy.
There were no significant differences in the rates of
complete remission, estimated overall survival, disease-
free survival, and event-free survival between patients
who received bone marrow transplantation and those
who continued with the conventional therapy.
The number of patients randomized was only suffi-
cient to show the expected difference in outcome of 35
percent between the two treatment methods. The rela-
tive risk of death in the transplantation group as com-
pared with the CHOP group was 2.2 (95 percent con-
fidence interval, 0.8 to 5.9). This value corresponds to
a difference in the probability of overall survival of 23
percent (95 percent confidence interval, 	5 percent to
58 percent), if a 70 percent probability of long-term
overall survival in the CHOP group is assumed. This
result implies that a small benefit of transplantation
cannot be excluded, but any substantial benefit is ex-
tremely unlikely. Considering the cost of bone marrow
transplantation and the failure of this very intensive
treatment to improve overall survival and disease-free
survival, we conclude that the early use of transplanta-
tion in patients with slow responses is not useful. It re-
mains to be clarified whether autologous bone marrow
transplantation may have a role among patients in the
recently defined high-risk subgroup of the international
Figure 2. Event-free Survival from the Time of Randomization,
According to Treatment Group.
Among 35 patients assigned to receive eight courses of CHOP
and 34 patients assigned to receive high-dose chemoradiother-
apy and autologous bone marrow transplantation, there were 15
and 18 treatment failures, respectively.
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Figure 3. Overall Survival among All Eligible Patients from the
Start of the First Course of CHOP.
Among 286 eligible patients, there were 105 deaths.
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index who have very poor survival after conventional
first-line chemotherapy or among patients with a re-
sponse but with proved residual disease after first-line
chemotherapy. 
When our study began, it was suggested that patients
with aggressive non-Hodgkin’s lymphoma19,20 or other
hematologic cancers24,25 who had complete responses
rapidly might have a better probability of cure than
those with slower responses to chemotherapy. A recent
comprehensive review of several phase 2 studies sup-
ports this hypothesis.26 The ability to stratify patients
early in the course of disease as being at either high or
low risk appears clinically important; high-risk patients
may benefit from experimental approaches such as
high-dose therapy with transplantation, whereas low-
risk patients should not receive unusually hazardous
treatments. With its international index, the Interna-
tional Non-Hodgkin’s Lymphoma Prognostic Factors
Project has defined factors present at diagnosis that
distinguish patients in groups with good, intermediate,
or poor survival.23 The value of these prognostic factors
was confirmed in our study; application of the interna-
tional index to all study patients gave probabilities of
four-year overall survival comparable to those reported
by the international index,23 ranging from 78 percent in
the low-risk group to 24 percent in the high-risk group
(data not shown).
Although 106 patients were eligible for random as-
signment to transplantation or to another five courses
of CHOP, only 69 patients (65 percent) were actually
randomized. Thus, 37 patients were not randomized,
mainly because the patients declined randomization.
There were no significant differences in rates of com-
plete remission or overall, disease-free, or event-free
survival between patients who were randomly assigned
to the two treatment groups, or among the two groups
and the 37 nonrandomized patients who also received
five more courses of CHOP. In fact, the estimated rates
of disease-free and event-free survival at four years
were 72 and 53 percent, respectively, for the random-
ized CHOP group and 60 and 41 percent for the trans-
plantation group, as compared with 70 and 43 percent
for the 37 nonrandomized patients. Procedure-related
deaths occurred in 6 percent of the transplantation
group; mortality was similar (5 percent) in the nonran-
domized CHOP groups. Probably by chance, proce-
dure-related deaths did not occur in the randomized
CHOP group. Furthermore, 54 percent of the nonran-
domized group of patients with fast responses (those in
complete remission after three courses of CHOP) who
continued with another five courses of CHOP were
alive without disease at four years. Thus, those who re-
sponded slowly did as well as those who responded rap-
idly. Apparently, it was the fact that they had complete
remissions that was predictive of outcome, rather than
the time required to attain them. Although most phase
2 studies of the value of a rapid response reported that
the speed with which patients achieved complete remis-
sions was an important prognostic factor,19,20,26 two
studies could not confirm this finding.26 This discrep-
ancy may be caused by the follow-up periods, which
were relatively short in most of these studies.
We are aware of only two other studies in which
high-dose therapy and autologous bone marrow trans-
plantation were compared with chemotherapy in
patients with aggressive non-Hodgkin’s lymphoma. In
these studies transplantation was not used early, but
was applied after the completion of conventional che-
motherapy. A multicenter Italian study27 compared
high-dose chemotherapy and transplantation with sal-
vage chemotherapy in patients who were in partial
remission after the completion of first-line chemothera-
py. The results suggested a better disease-free survival
for the transplantation group. A multicenter French
study28 compared intensive, but not marrow-ablative,
chemotherapy and bone marrow transplantation with
intensive sequential chemotherapy in patients who were
in complete remission after first-line chemotherapy.
This study found no difference in disease-free survival
between the two treatments. Although both studies dif-
fer from this one on several points, their data suggest
that high-dose therapy combined with bone marrow
transplantation does not improve outcome in patients
who are in either very good partial remission (with re-
sidual abnormalities of unknown importance) or com-
plete remission after chemotherapy.
We conclude that the early use of marrow-ablative
chemoradiotherapy with autologous bone marrow trans-
plantation offers no significant benefit in patients with
aggressive non-Hodgkin’s lymphoma who have re-
sponded slowly to first-line chemotherapy. Further-
more, the rapidity with which complete remission is
achieved appears to have no prognostic importance.
We are indebted to Jan A.M. van Unnik for skillful central pathol-
ogy review, to Margriet Bongers for central data management, to the
Comprehensive Cancer Centers in the Netherlands for assistance
with data management, to Piet van Assendelft for the construction of
a data base, and to Joukje van der Velde for assistance in the prepa-
ration of the manuscript.
Figure 4. Overall Survival from the Time of Evaluation among All
Eligible Patients, According to the Response after Three Cours-
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